Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patients

被引：0
|
作者：
Biscanin, A. [1 ,2 ]
Tomasic, V. [1 ]
Babic, F. [1 ]
Cacic, P. [1 ]
Kordej, D. Ogresta [1 ]
Hrabar, D. [1 ,2 ]
Kralj, D. [1 ]
Dorosulic, Z. [1 ]
机构：
[1] Sisters Char Univ Hosp, Dept Gastroenterol, Zagreb, Croatia
[2] Univ Zagreb, Sch Med, Zagreb, Croatia
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P565
引用
收藏
页码：695 / 695
页数：1
相关论文
共 50 条
  • [41] The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF- naive Crohn's disease
    Narula, N.
    Kainz, S.
    Petritsch, W.
    Haas, T.
    Feichtenschlager, T.
    Novacek, G.
    Eser, A.
    Vogelsang, H.
    Reinisch, W.
    Papay, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (02) : 170 - 180
  • [42] Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease
    Narula, Neeraj
    Wong, Emily C. L.
    Dulai, Parambir S.
    Sengupta, Neil K.
    Marshall, John K.
    Colombel, Jean-Frederic
    Reinisch, Walter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (07) : 1579 - +
  • [43] Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease
    Rutgeerts, Paul
    Gasink, Christopher
    Chan, Daphne
    Lang, Yinghua
    Pollack, Paul
    Colombel, Jean-Frederic
    Wolf, Douglas C.
    Jacobstein, Douglas
    Johanns, Jewel
    Szapary, Philippe
    Adedokun, Omoniyi J.
    Feagan, Brian G.
    Sandborn, William J.
    GASTROENTEROLOGY, 2018, 155 (04) : 1045 - 1058
  • [44] Adalimumab: the efficacy and safety in Crohn's disease
    Foster, R.
    Ambikaipaker, V.
    Radvan, G.
    Lawrence, O.
    Daley, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A87 - A87
  • [45] DELAYED USTEKINUMAB AND ADALIMUMAB RESPONDERS HAVE SIMILAR OUTCOMES AS EARLY RESPONDERS IN BIOLOGIC-NAIVE CROHN'S DISEASE
    Narula, Neeraj
    Wong, Emily C.
    Dulai, Parambir S.
    Marshall, John K.
    Jairath, Vipul
    Reinisch, Walter
    GASTROENTEROLOGY, 2024, 166 (05) : S1430 - S1430
  • [46] PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG BIO-EXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB COMPARED TO ADALIMUMAB
    Zhdanava, Maryia
    Ding, Zhijie
    Manceur, Ameur
    Kachroo, Sumesh
    Holiday, Christopher
    Zhao, Ruizhi
    Pilon, Dominic
    GASTROENTEROLOGY, 2023, 164 (04) : S45 - S46
  • [47] PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG BIO-EXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB COMPARED TO ADALIMUMAB
    Zhdanava, Maryia
    Ding, Zhijie
    Manceur, Ameur
    Kachroo, Sumesh
    Holiday, Christopher
    Zhao, Ruizhi
    Pilon, Dominic
    INFLAMMATORY BOWEL DISEASES, 2023, 29 : S36 - S36
  • [48] Response to Adalimumab Therapy in bio-naive patients and in Infliximab nonresponders: Results of a Phase Illb Clinical Trial
    Lofberg, R.
    Louis, E.
    Reinisch, W.
    Kron, M.
    Camez, A.
    Pollack, P.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S27 - S28
  • [49] DIRECT COMPARISON OF FOUR BIOLOGICAL AGENTS IN BIO-NAIVE RHEUMATOID ARTHRITIS PATIENTS
    Yonemoto, Y.
    Okamura, K.
    Takeuchi, K.
    Matsushita, M.
    Kaneko, T.
    Kobayashi, T.
    Aramaki, T.
    Takagishi, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 185 - 185
  • [50] NONBIOLOGIC DRUG USE BEFORE AND AFTER INITIATION OF USTEKINUMAB OR ADALIMUMAB FOR CROHN'S DISEASE PATIENTS
    Obando, Camilo
    Ding, Zhijie
    Muser, Erik
    Slaton, Terra
    Kozma, Chris
    GASTROENTEROLOGY, 2019, 156 (06) : S882 - S882
12345